Z
Zhe-Sheng Chen
H指数:99
被引数:4.1万
个人简介
Dr. Zhe-Sheng (Jason) Chen, M.D., PhD, is currently a Professor at College of Pharmacy and Health Sciences, St. John's University. He joined St. John's University in 2004 as an assistant professor. He established several research projects to study ABC transporters and multidrug resistance (MDR) as well as reversal of MDR in both in vitro and in vivo tumor models. During past years, his laboratory has been well funded by NIH and companies. He carried out his postdoctoral training at Fox Chase Cancer Center (Philadelphia, USA, 2000-2004) and Kagoshima University Faculty of Medicine (Japan, 1998-2000). He received his Ph.D. degree from Kagoshima University Faculty of Medicine (Japan, 1994-1998), Master degree from Sun Yat-Sen University School of Public Health (China, 1985-1988) and M.D. from Guangdong Medical and Pharmaceutical College (China, 1980-1985). Dr. Chen is an editor-in-chief of Journal of Cancer Research Updates, and New Developments on Chemistry, an editor of African Journal of Pharmacy and Pharmacology, Regional Editor of Recent Patents on Anticancer Drugs Discovery, a guest editor of Current Pharmaceutical Biotechnology, an editorial board member of more than 20 journals and a reviewer of more than 170 peer reviewed journals. He is also an Ad hoc reviewer of some grants such as NIH, NCI Special Emphasis Review Panel, OmniBus SEP-10, State Grant Reviewer for Louisiana, and grants for New Zealand, Poland, China, Hungary, and Netherlands etc. As a consultant to pharmaceutical, biotechnology and health industry organizations, Dr. Chen commands invitations for presentations, keynote addresses, and conference chairman. He published more than 150 publications in peer reviewed journals and 5 book chapters.
教育背景
暂无内容
工作经历
2004.01 – 至今
St. John’s University
Professor
荣誉奖项
暂无内容
在人工智能时代,我们是否还需要自己绘制示意图?
Innovation
IF25.7
聚乙二醇洛塞那肽在2型糖尿病中的真实世界肾脏保护作用:一项多中心、双向性队列研究
癌症治疗抵抗的神经程序:一种以机制为先的靶向治疗框架
Drug Resistance Updates
IF21.7
从结构修饰到多样药理活性:胆汁酸的最新进展与未来展望
940-nm光生物调节通过TRPV1相关钙信号和线粒体氧化还原重塑增强ADSC介导的气管软骨修复
Research
IF10.7
癌症中的半胱氨酸获取:半胱氨酸输入还是谷胱甘肽分解代谢?
Drug Resistance Updates
IF21.7
肿瘤源性CTHRC1介导ITGB3依赖性破骨细胞分化以促进前列腺癌骨转移
Oncogene
IF7.3
衣康酸及其衍生物在人类健康和疾病中的作用
Golvatinib(E7050)通过抑制ABCG2转运蛋白恢复多药耐药癌细胞的化疗敏感性
ABCB1过表达赋予对litronesib(一种Eg5抑制剂)的耐药性
癌症放射治疗中的药物耐药性:从机制到克服策略
Pharmacological Research
IF10.5
绞股蓝皂苷V通过结合ITGB1并介导PURA-eNOS激活改善糖尿病小鼠的血管内皮功能障碍
Phytomedicine
IF8.3
Vactosertib通过双重抑制药物外排和转运蛋白表达逆转ABCG2介导的多药耐药
抗体药物偶联物对抗多药耐药癌症:生物标志物指导的患者选择、载荷工程、连接子化学和旁观者效应
Cancer Letters
IF10.1
基于新型免疫检查点的新型生物标志物可预测“驱动基因阴性”肺腺癌的免疫治疗效果
Cancer Letters
IF10.1
导航HIV-1药物抗性:蛋白酶抑制剂疗效和突变动态的全面综述
Drug Discovery Today
IF7.5
适应性谱系可塑性驱动对KRAS-EGFR靶向疗法的多药耐药性
Drug Resistance Updates
IF21.7
类风湿关节炎诱导的心血管风险管理中改善病情抗风湿药(DMARDs)的作用
肿瘤相关巨噬细胞的分子PET成像在精准肿瘤学中的应用
Cancer Letters
IF10.1
MTSS1-dependent FBXO44介导的泛素修饰重塑肌动蛋白细胞骨架促进胃癌进展
Molecular Cancer
IF33.9

